Female Health Co  

(Public, NASDAQ:FHCO)   Watch this stock  
Find more results for female
+0.08 (7.55%)
Jul 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.12 - 1.21
52 week 0.72 - 1.65
Open 1.12
Vol / Avg. 245,913.00/39,270.00
Mkt cap 35.73M
P/E     -
Div/yield     -
EPS -0.14
Shares 31.34M
Beta 1.38
Inst. own 9%
May 9, 2017
Q2 2017 Female Health Co Earnings Call - Webcast
Apr 28, 2017
Q2 2017 Female Health Co Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -73.86% 1.56%
Operating margin -107.22% 13.64%
EBITD margin - 22.25%
Return on average assets -12.10% 0.91%
Return on average equity -20.72% 1.03%
Employees 155 -
CDP Score - -


4400 Biscayne Blvd Ste 888
MIAMI, FL 33137-3212
United States - Map
+1-312-5959123 (Phone)
+1-312-5959122 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


The Female Health Company is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men's and women's health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women's Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS). Its first generation product is the FC1 Female Condom.

Officers and directors

Elgar Peerschke Chairman of the Board
Bio & Compensation  - Reuters
Mitchell S. Steiner M.D. President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
Overton B. Parrish Jr. Vice Chairman of the Board
Age: 82
Bio & Compensation  - Reuters
Daniel Haines Chief Financial Officer, Chief Operating Officer
Bio & Compensation  - Reuters
Mario Eisenberger Director
Bio & Compensation  - Reuters
Harry Fisch M.D. Director
Bio & Compensation  - Reuters
Lucy Lu M.D. Director
Age: 40
Bio & Compensation  - Reuters
Georges Makhoul Director
Bio & Compensation  - Reuters
David R. Bethune Independent Director
Age: 75
Bio & Compensation  - Reuters